Aarey Drugs & Pharmaceuticals Limited reported a sharp expansion in top-line growth for the quarter ended June 30, 2026, with revenue rising 145% year-on-year. However, this volume surge was not matched by profitability, as net profit before tax contracted significantly.

**Aarey Drugs & Pharmaceuticals Limited** posted total income from operations of ₹4,643.05 lakh for Q1FY26, compared to ₹1,894.29 lakh in the corresponding quarter of FY25. Despite the robust revenue performance, the company’s net profit before tax, exceptional and extraordinary items fell 59.7% to ₹51.56 lakh, down from ₹128.01 lakh in Q1FY25.

Financial Performance Overview

The company’s full-year audited results for FY26 showed total income of ₹10,736.08 lakh and a net profit before tax of ₹137.72 lakh. For the current quarter, earnings per share (basic and diluted) stood at ₹0.36 each, marginally higher than the ₹0.35 recorded in Q1FY25.

What the Numbers Show

The divergence between revenue growth and profit contraction indicates significant margin compression during the quarter. While sales more than doubled, the absolute profit contribution dropped by nearly 60%. This suggests that cost structures or input prices may have risen disproportionately to the revenue gains, eroding operational efficiency despite the strong topline momentum.

Corporate Governance

The Board of Directors approved the unaudited standalone financial results at its meeting held on August 14, 2026. The results were reviewed by the Audit Committee in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed financial statements are available on the company’s website and stock exchange portals.

Aarey Drugs & Pharmaceuticals reported a net profit of ₹396.76 lakh for the financial year ended March 31, 2026, compared to ₹402.39 lakh in the previous year. Revenue from operations for the year stood at ₹47,226.90 lakh, a slight decrease from ₹47,394.33 lakh in FY25. The board approved the audited standalone financial results for the fourth quarter and year ended March 31, 2026, at its meeting held on May 30, 2026. The company published an extract of the audited standalone financial results in "Active Times" and "Mumbai Lakshadweep" on June 2, 2026, in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For the quarter ended March 31, 2026, the company recorded a net profit of ₹155.74 lakh, a significant increase from ₹47.01 lakh in the same period last year. Revenue from operations for Q4FY26 surged to ₹18,947.24 lakh from ₹10,809.93 lakh in Q4FY25. The total income for the quarter was ₹18,904.29 lakh.

Financial Performance

The company's total expenses for FY26 were ₹47,295.19 lakh, marginally lower than ₹47,765.38 lakh in the previous year. Profit before tax for the year was ₹541.42 lakh, down from ₹610.19 lakh in FY25. The board also considered the statement of deviation or variation in the utilization of funds raised through convertible warrants.

Key Metrics

Auditor's Report

Statutory auditors Motilal & Associates LLP issued an audit report with an unmodified opinion on the financial results. The auditors emphasized that closing balances for debtors and creditors are subject to confirmation and relied upon management representation where confirmations were not available. The trading window, which was closed prior to the board meeting, will reopen 48 hours after the announcement of the results.